Cemiplimab-Rwlc
Sponsors
Alaunos Therapeutics, H. Lee Moffitt Cancer Center and Research Institute, Wake Forest University Health Sciences, University of Miami, Baptist Health South Florida
Conditions
Advanced Squamous Cell CarcinomaCutaneous Squamous Cell CarcinomaCutaneous Squamous Cell Carcinoma of the Head and NeckGlioblastomaHNSCCHead and Neck Squamous Cell CarcinomaMerkel Cell CarcinomaNon-small Cell Lung Cancer Stage III
Phase 1
Neoadjuvant Cemiplimab in Newly Diagnosed or Recurrent Stage I-II Merkel Cell Carcinoma and Locoregionally Advanced Cutaneous Squamous Cell Carcinoma
RecruitingNCT04975152
Start: 2021-10-22End: 2028-03-01Target: 36Updated: 2026-06-25
Cemiplimab/Peg-Interferon-α in Advanced CSCC
WithdrawnNCT05729139
Start: 2023-07-31End: 2028-07-31Updated: 2023-08-09
Phase 2
Study of Ad-RTS-hIL-12 + Veledimex in Combination With Cemiplimab in Subjects With Recurrent or Progressive Glioblastoma
TerminatedNCT04006119
Start: 2019-08-01End: 2021-08-05Updated: 2025-04-18
Cemiplimab-rwlc for Unresectable Locally Recurrent and/or Metastatic CSCC
TerminatedNCT04242173
Start: 2020-06-25End: 2022-05-26Updated: 2022-11-04
Pilot Study of Performance Status 2 vs. Performance Status 0-1 Non-small Cell Lung Cancer Patients Treated With Chemo/Immunotherapy
RecruitingNCT04253964
Start: 2020-07-01End: 2027-09-01Target: 105Updated: 2026-08-10
Phase 2 Trial of Maintenance Cemiplimab for Head and Neck Squamous Cell Carcinoma (HNSCC)
WithdrawnNCT04831450
Start: 2022-07-31End: 2022-07-15Updated: 2022-08-04
Neoadjuvant Chemo-Immunotherapy and Surgical Resection in Locally Advanced Non-small Cell Lung Cancer With N3 Lymph Node or Other High Risk Features
RecruitingNCT06449313
Start: 2026-08-01End: 2032-09-01Target: 21Updated: 2026-08-05